Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
DNA polymerase epsilon-mutant colorectal cancers: Insights into non-exonuclease domain mutation variants, microsatellite instability status, and co-mutation profiles.
Taskiran I et al.
World Journal of Gastroenterology, 2025
Mutational profiling using liquid biopsy to guide targeted therapy in patients with metastatic cancer.
Mazouji O et al.
Scientific Reports, 2025
TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression.
Bi J et al.
Nature Communications, 2023
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
Du Z et al.
Nature Communications, 2021
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020
Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort.
Shen HB et al.
Cancer Management and Research, 2020
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer.
Hu AM et al.
Chinese Medical Journal, 2018
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2017
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.
Park E et al.
Nature Structural & Molecular Biology, 2015
Integrated analysis of germline and somatic variants in ovarian cancer.
Kanchi KL et al.
Nature Communications, 2014
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.
Singh RR et al.
The Journal of Molecular Diagnostics : Jmd, 2013
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation.
Kancha RK et al.
Cell Communication and Signaling : Ccs, 2013
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.
Do H et al.
Molecular Cancer, 2009